First “human challenge trial” of deliberately infected with the COVID-19 proved to be safe
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
- NK Cells: Unveiling a Multifaceted Medical Marvel for Stroke Recovery and Beyond
- Japan’s Shift to Regular COVID-19 Vaccination for Elderly
- Active Monitoring vs. Surgery for Moderate Cervical Lesions
- Probiotics Linked to Immune Suppression and Tumor Growth
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
First “human challenge trial” of deliberately infected with the COVID-19 proved to be safe
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The world’s first “human challenge trial” of deliberately infected with the COVID-19 proved to be safe
According to British media reports, in the early days of the outbreak, some researchers had called for a rapid method to determine whether a COVID-19 vaccine was effective, that is, inoculating volunteers to actively infect the virus and promote further research on the COVID-19 virus.
On February 2, local time, the research team responsible for the world’s first human challenge trial said that the trial of active infection with the new coronavirus is safe for healthy young volunteers.
The one-year trial is being carried out by Irish pharmaceutical company Open Orphan in conjunction with Imperial College London, the UK government’s vaccine task force and clinical company hVIVO.
The research team added that these data support the safety of the model and lay the foundation for future research on the new coronavirus.
In this landmark “human challenge study”, 36 volunteers aged 18 to 29 who had never been infected with the new coronavirus were infected with a small dose of the new coronavirus through nasal drops.
It was found that 18 volunteers were infected, and 16 of them subsequently developed mild to moderate cold-like symptoms, including nasal congestion or runny nose, sneezing and sore throat.
Some people also experienced headaches, muscle/joint pain, tiredness and fever. But no one developed severe symptoms.
In addition, 13 infected volunteers temporarily lost their sense of smell, but within 90 days, all but three of the participants had regained their sense of smell. All three volunteers showed improvement after three months.
The researchers found that symptoms appeared very quickly after infection, taking only two days on average.
Specifically, the virus first appeared in the throat, and then the viral load peaked around day five.
This is also the stage when the most obvious symptoms usually appear. At this stage, the viral load in the nasal cavity is already significantly higher than in the throat. The average survival time of the virus in the nasal cavity of most people is 6.5 days.
So far, experts, including those from the World Health Organization (WHO), generally agree that it takes five to six days for a person to develop symptoms of the new coronavirus.
The research team said they are now beginning to work on other parts of the trial, including investigating why 16 of the 34 participants did not become infected after being exposed to the virus; some had the virus detectable in their nasal passages but not in nucleic acid testing positive.
The world’s first “human challenge trial” of deliberately infected with the COVID-19 proved to be safe
(source:internet, reference only)
Disclaimer of medicaltrend.org
